UNIVERSITY OF SOUTH FLORIDA

New Phase 3 RISE-PD study data reveals CREXONT (carbidopa/levodopa extended-release) significantly improved sleep quality in Parkinson's disease patients compared to immediate-release formulations, with a mean difference of -2.35 in PDSS-2 scores (p<0.0001).

Phase 3 LIBERTY-CSU CUPID trials demonstrate dupilumab's effectiveness in reducing itch and urticaria activity in patients unresponsive to H1-antihistamines.

Leading hospitals across North America are actively engaged in clinical trials to find effective treatments for trigeminal neuralgia, a condition causing severe facial pain.